Tagged with VAT

Poland Stefan Jaworski-Martycz, country manager Poland and CEE Cluster Lead of Théa, a leading French ophthalmology company, discusses the intricacies of the Polish ophthalmology environment and the key steps for the Polish government to better value eyecare innovation. Additionally, he highlights the key growth drivers for the affiliate and the close…

Baltics Evija Buksa, general manager at Merck in Latvia, explains the strong history of Merck in the country as well as its key role in participating in the discussions to shape the Latvian healthcare system. Could you please start by introducing Merck in Latvia and the strategic significance of the local…

UK Much of the new inward investment in the UK from international pharmaceutical companies is from those that wish their discovery science to be in close adjacency to the most successful basic science programmes in biomedicinein the world. The co-location of pharmaceutical discovery sciences adjacent to the best universities (AstraZeneca in Cambridge, Novo Nordisk…

Canada Canadian medtech at a glance: market value, number of companies, number of employees,export markets, spinoffs.   Key areas of expenditure in Canadian medtech: diagnostic imaging stands as the single largest therapeutic area served.   Canadian medical device export destinations; the US is far and away the largest market for Canadian…

Poland Dorota Hryniewiecka-Firlej, president of Pfizer Poland, discusses the current state of the Polish innovation landscape and importance of a tight-knit relationship between the innovative pharmaceutical market and the government for better patient outcomes. Furthermore, she highlights the strong R&D footprint of Pfizer Poland and their role in facilitating a domestic…

Baltics SIFFA’s Valters Bolēvics discusses Latvia’s competitiveness in embracing medical innovations, current healthcare reforms, and the country’s enduring potential as a pharmaceutical investment destination. The Association of International Research-based Pharmaceutical Manufacturers (SIFFA) was initially founded in 1996 to act as a united voice for five multinationals that had penetrated the local…

Poland Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment strategy to assure the company’s impressive growth. Furthermore, he surveys the Polish R&D landscape and discusses the importance of a…

Brazil Maria del Pilar Muñoz, vice-president in charge of M&A and Sustainability at Eurofarma, one of the largest and most innovative pharmaceutical companies in Brazil with operations in 20 countries across Latin Americ , provides insights into the key competitive advantages of Eurofarma, its unique internationalization strategy, and the company’s historical…

Switzerland As the spotlight turns towards optimising supply and delivery chains in pharma logistics, Swiss Post has distinguished itself as one of the early movers in trialling autonomous drone logistics for commercial purposes. In March 2017, the company and its partner, Matternet, received clearance from the Swiss aviation authority to fly…

Canada Jean-Philippe Gentès, President, and CEO of the rapidly growing ready-to-use injectable manufacturer Sterinova, shares his ideas on the ‘Made in Canada’ label, innovation in North America and the pros and cons of pricing pressures in healthcare. Sterinova is a prime example of Made in Canada innovation, although Canadian innovation sometimes…

Lithuania Martynas Jocys, Baltics marketing director and Lithuania general manager at AstraZeneca, talks about the role that innovation has played in the company’s strategy, the need for increased patient access in Lithuania and the other Baltic countries as well as the launch of new products for oncology, biologics, severe asthma, diabetes,…

Canada Oliver Technow, president at BioVectra, highlights the company’s recent developments; amongst those a significant investment in a manufacturing site near Halifax. The resulting increase in manufacturing capacity by 40 percent will add to BioVectra’s position as the largest biotechnology company on Prince Edward Island, a historic location the CDMO is…